Regional Oncology Practices Are Quietly Selling to Health System Networks

The Quiet Exit From Independent Oncology

Across the country, independent oncology practices that have operated for decades under physician ownership are signing acquisition agreements with large health system networks. The transactions rarely make headlines. There are no press conferences, no public filings in most cases, and no announcement beyond a letter to patients explaining that their care team is “joining” a larger organization. But the volume and pace of these deals has accelerated noticeably, and the reasons behind them say a great deal about where cancer care is heading financially.

The economics of running an independent oncology practice have become genuinely difficult to sustain.

Drug acquisition costs sit at the center of the problem. Oncology practices generate a significant portion of their revenue not from office visits but from the margin between what they pay for chemotherapy drugs and what they bill insurers. That margin, known as “buy-and-bill,” has been compressed steadily as payers tighten reimbursement rates and pharmaceutical manufacturers adjust contract terms. For a small or mid-sized practice without the negotiating scale of a major health system, the financial cushion that once made independent operation viable has thinned to the point where long-term planning becomes nearly impossible.

Why Health Systems Are Buying Now

Health systems have strategic reasons to pursue these acquisitions aggressively. Oncology generates some of the highest per-patient revenue of any specialty, and acquiring established practices gives health networks both the patient volume and the referral pipelines that would take years to build organically. A regional cancer center brought under a health system umbrella immediately feeds surgical oncology, radiation, pathology, imaging, and inpatient services – all of which sit within the acquiring organization. The financial case for the buyer is straightforward.

For the selling physicians, the calculation is more complicated. Many oncologists who built their own practices over 20 or 30 years are facing a choice between selling now at a reasonable valuation or watching their leverage deteriorate further as payer pressure continues. Physician owners who are approaching retirement have particular incentive to transact while their practices still carry meaningful goodwill value. Younger partners, meanwhile, may prefer the stability of a salary and benefits structure over the financial exposure that comes with ownership – especially given how capital-intensive oncology has become with the expansion of oral chemotherapy agents and precision medicine diagnostics.

The health system also offers something increasingly hard to replicate independently: access to clinical trial infrastructure, advanced imaging technology, and multi-disciplinary tumor board resources. Patients being treated for complex cancers increasingly expect those capabilities, and a solo or small-group practice simply cannot fund them at scale. That gap in capability – not just the financial pressure – is quietly pushing physician owners toward the negotiating table.

What Changes After the Sale

The transition from independent to health-system-owned is rarely seamless for patients or staff, despite how acquisition agreements tend to be framed publicly. Billing changes immediately, and patients who previously paid one set of cost-sharing rates often find themselves subject to hospital outpatient department pricing, which can be significantly higher for the same infusion services. This is the same mechanism playing out in other specialty areas – regional surgery centers have been navigating comparable contract conflicts with commercial insurers as facility-based pricing structures shift the cost burden onto patients.

Physician autonomy is another casualty of integration that gets underplayed in deal announcements. Oncologists who previously made clinical and operational decisions independently find themselves working within committee-based approval structures. Formulary decisions, staffing ratios, scheduling templates, and even which clinical trials a practice participates in become system-level choices rather than physician-level ones. Some oncologists adapt to this quickly. Others leave within 18 to 24 months of acquisition, creating the exact continuity problem for patients that the acquiring health system was supposed to solve.

Staff turnover patterns at acquired practices are worth watching. When a practice changes ownership, administrative and clinical support staff often face restructured compensation, new HR systems, and different management cultures. High turnover in nursing and patient navigation roles can disrupt the care coordination that oncology patients depend on especially during active treatment cycles. The quality of a cancer care practice is not just its physicians – it is the entire team that manages appointments, authorizations, symptom calls, and drug delivery scheduling. Disrupting that structure mid-acquisition creates real risk that no deal press release addresses directly.

The Structural Consolidation Nobody Is Talking About

What is happening across regional oncology is not a series of isolated business decisions – it is a structural consolidation of cancer care delivery into the hands of a smaller number of very large institutions, and the long-term effect on access, pricing, and physician supply in non-urban markets remains genuinely unresolved. When the last independent oncology practice in a mid-sized city sells to the regional health system, that system becomes the only game in town, and the negotiating dynamics with both payers and patients shift accordingly.